Journal Alzheimer’s Research & Therapy has announced that it is now accepting research submissions for consideration in a special series on Lewy body dementia (LBD), planned for publication in mid-2014.
The publication of these articles will be co-ordinated with a series of commissioned reviews and opinions, guest edited by co-Series Editors Prof Ian McKeith (Newcastle University, UK) and Prof James Galvin (NYU, USA), and written by leaders in the field including John O’Brien (Cambridge University, UK), Brit Mollenhauer (Paracelsus Elena Klinik, Germany) and Glenda Halliday (Neuroscience Research Australia).
This special series in Alzheimer’s Research & Therapy takes a translational view of LBD from bedside to bench and back. The journal welcomes research manuscripts to accompany a series of articles that review clinical and cognitive characteristics, prodromal states, synuclein biology and genetics, biomarkers, impact of the disease on patients and caregivers and the role of advocacy groups to raise awareness.
The deadline for submissions is April 30, 2014. Researchers are requested to submit online and indicate in their covering letter that they would like the article to be considered for the Lewy body dementia series.
The stated benefits of publishing in Alzheimer’s Research & Therapy include: Impact Factor of 4.39 ranks the journal as the leading Alzheimer’s-disease specific journal in the neurosciences field (Journal Citation Reports); rapid peer–review (first decision provided within 6 weeks); prestigious and international Editorial Board; immediate publication on acceptance, no colour figure charges or space limits and unlimited global accessibility and high visibility for your research that open access publishing provides; and inclusion in PubMed and PubMed Central and indexed in Web of Science database/Science citation index Expanded (SciSearch).
